Author of

• 25925

  +

  P1.05 - Interventional Diagnostics/Pulmonology (Not CME Accredited Session) (ID 937)

  • Event: WCLC 2018
  • Type: Poster Viewing in the Exhibit Hall
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall

  • 26494

    +

    P1.05-17 - Clinicopathological Characteristics of Primary Lung Cancers Associated with Emphysematous Bullae (ID 13204)

    16:45 - 18:00  |  Presenting Author(s): Mikito Suzuki
    • Abstract
    • Slides

    Background
    

    Lung cancers associated with emphysematous bullae (EB) comprise approximately 5% of all primary lung cancers, but the clinicopathological characteristics remain unclear. This study aims to investigate the clinicopathological characteristics and postoperative prognosis of lung cancers associated with EB.

    a9ded1e5ce5d75814730bb4caaf49419 Method
    

    From 2008 through 2012, consecutive 517 patients who underwent complete surgical resection for primary lung cancer at our institution, were retrospectively reviewed. Lung cancer associated with EB was defined as lung cancer adjoining emphysematous airspace >1cm, without lung parenchyma, on preoperative thin-slice computed tomography scans. Among the 517 patients, 35 (6.8%) had lung cancers associated with EB (EB group). Their clinicopathological features and prognosis were retrospectively compared with those in the patients having lung cancer not associated with EB (non-EB group).

    4c3880bb027f159e801041b1021e88e8 Result
    

    The median follow-up duration was 42 months (range, 2-85 months). The median age of EB group was 70 (39-79) years, while that for non-EB group was younger 59 (33-91) years (p = 0.07). The EB group included more men (94% vs. 6%, p < 0.01), smokers (97% vs 63%, p < 0.01), and the patients with low FEV1.0% (< 70%) ( 91% vs 27%, p < 0.01). In the EB group, frequency of cancer in the right upper lobe was significantly higher than in the non-EB group (60% vs 25%, p < 0.01). Histologically, non-adenocarcinomas, including squamous cell carcinoma, neuroendocrine tumor and large cell carcinoma, were common in the EB group compared with in the non-EB group (57% vs 24%, p < 0.01). Among the EB group, 16 patients (45%) were p-stage I, 16 (45%) were p-stage II, three (9%) were p-stage III, and none (0%) were p-stage IV (WHO 8^th classification). The 5-year overall survival (OS) rate for EB and non-EB groups was 75% and 88%, respectively, without significant difference (p = 0.20). The 5-year recurrence-free survival (RFS) rate was also not different between EB and non-EB groups (75% vs. 79%, p = 0.85). The multivariate analysis did not demonstrate that the association with EB to be a significant prognostic factor (p = 0.39).

    8eea62084ca7e541d918e823422bd82e Conclusion
    

    Lung cancers associated with EB have clinicopathological features including the predominance of men, heavy-smoking history, and non-adenocarcinoma histology compared with lung cancer not associated with EB. However, in the current analysis, the survival was not different between patients with lung cancers with and without EB.

    6f8b794f3246b0c1e1780bb4d4d5dc53

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.